Condition: Pancreas Cancer · Sponsor: Shandong Cancer Hospital and Institute
Hypothesis: Survival benefits could be found in Sintilimab plus chemotherapy and radiotherapy in patients with inoperable pancreatic cancer.
This description comes directly from the study's public registry record.
Jinbo Yue, dorctor · 0531-67626442 · yuejinbo@hotmail.com
Lei Xu, dorctor · 0531-67626442 · Len.Xu@hotmail.com
Always discuss trial participation with your own doctor first.
| Department of Radiation Oncology, Shandong Cancer Hospital and Institute | Jinan, Shandong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06050317